medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2005, Number 3

<< Back Next >>

Ann Hepatol 2005; 4 (3)

Current concepts in the management and treatment of hepatitis C in HIV-infected patients

Núñez M, Soriano V

Language: English
References: 92
Page: 151-160
PDF size: 97.59 Kb.


Text Extraction

Chronic hepatitis C virus (HCV) infection is very common among HIV-positive patients who were infected through intravenous drugs use or contaminated blood products (e.g., hemophiliacs). An increase in liver-related deaths among HIV-positive subjects co-infected with HCV has been acknowledged over the last years. HIV infection has a negative impact on the natural history of chronic hepatitis C, accelerating the progression of liver fibrosis. Moreover, interactions between anti-HIV and anti-HCV drugs are of concern, and a lower response to anti-HCV therapy limits its benefit in the HIV/HCV-coinfected population. Regarding treatment monitoring, the stopping rule at week 12 recommended for HCV-monoinfected individuals, seems to be equally valid in HIV-infected patients. This finding is of great value, since it allows to offer treatment in the absence of contraindication (e.g., low CD4 counts, alcohol abuse, etc), discontinuing it as soon as at 12 weeks after initiation when no chances of cure are anticipated, saving costs and deleterious side effects. There are important barriers to HCV treatment in HIV/HCV-coinfected patients, which are necessary to be addressed in order to increase the eligibility and applicability of HCV therapy in this population. In addition, strategies aimed to improve tolerance of the HCV medication with adequate support as well as to enhance the response to current available therapies, including individualized tailoring of drug dosages and length of treatment, should be pursuit to enhance the rate of treatment success. Finally, new anti-HCV drugs currently under development are eagerly awaited for the growing number of HCV/HIV-coinfected patients non-responders or relapsers to the current therapy.


REFERENCES

  1. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001; 32: 492-7.

  2. Cacoub P, Geffray L, Rosenthal E, et al. Mortality among HIV-infected patients with cirrhosis or hepatocellular carcinoma due to hepatitis C virus in French Departments of Internal Medicine/Infectious Diseases, in 1995 and 1997. Clin Infect Dis 2001; 32: 1207-14.

  3. Martín-Carbonero L, Soriano V, Valencia E, García-Samaniego J, López M, González-Lahoz J. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 2001; 17: 1467-72.

  4. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 2003; 17: 1803-9.

  5. Gebo K, Diener-West M, Moore R. Hospitalization rates differ by hepatitis C status in an urban HIV cohort. J Acquir Immune Defic Syndr 2003; 34: 165-73.

  6. Reisler R, Han C, Burman W, Tedaldi E, Neaton J. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003; 34: 379-86.

  7. Murphy E, Collier A, Kalish L, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001; 135: 17-26.

  8. Nuñez M, Soriano V. New hopes for HIV and HCV coinfection in 2004. HIV Clin Trials 2004; 5: 232-51.

  9. Cribier B, Rey D, Schmitt C, et al. High hepatitis C viremia and impaired antibody response in patients coinfected with HIV. AIDS 1995; 9: 1131-6.

  10. Bonacini M, Govindarajan S, Blatt L, Schmid P, Conrad A, Lindsay K. Patients coinfected with HIV and hepatitis C demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999; 6: 203-8.

  11. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in HIV and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30: 1054-8.

  12. Puoti M, Bonacini M, Spinetti A, et al. Liver fibrosis progression is related to CD4+ cells depletion in patients with hepatitis C and HIV coinfection. J Infect Dis 2001; 183:134-7.

  13. Martínez-Sierra C, Arizcorreta A, Díaz F, et al. Progression of chronic hepatitis C to liver fibrosis and cirrhosis in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2003; 36: 491-98.

  14. Martín-Cabonero L, Benhamou Y, Puoti M, et al. Incidence and predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C – a European collaborative study. Clin Infect Dis 2004; 38: 128-33.

  15. Eyster M, Diamondstone L, Lien J, et al. Natural history of hepatitis C virus infection in multi-transfused hemophiliacs: effect of coinfection with HIV. A multicenter hemophilia cohort study. J Acquir Immun Defic Syndr 1993; 6: 602-10.

  16. Sanchez-Quijano A, Andreu J, Gavilan S, et al. Influence of HIV type 1 infection on the natural history of chronic parenteral acquired hepatitis C. Eur J Clin Microbiol Infect Dis 1995; 14: 949-53.

  17. Rockstroh J, Spengler U, Sudhop T, et al. Immunosuppression may lead to progression of hepatitis C virus associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 1996; 91: 2563-8.

  18. Soto B, Sanchez-Quijano A, Rodrigo L et al. HIV infection modifies the natural history of chronic parenteral acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 1997; 26: 1-5.

  19. Garcia-Samaniego J, Rodriguez M, Berenguer J, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179-83.

  20. Tedaldi E, Baker R, Moorman A, et al. Influence of coinfection with HCV on morbidity and mortality due to HIV infection in the era of HAART. Clin Infect Dis 2003; 36: 363-7.

  21. Dronda F, Zamora J, Moreno S, et al. CD4 cell recovery during successful antiretroviral therapy in naive HIV-infected patients: the role of intravenous drug use. AIDS 2004; 18: 2210-2.

  22. Nuñez M, Soriano V. Hepatotoxicity of antiretrovirals. Incidence, mechanisms and management. Drug Safety 2005; 28: 53-66.

  23. Bräu N. Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy. AIDS 2003; 17: 2279-90.

  24. Rockstroh J, Spengler U. HIV/HCV coinfection. Lancet Infect Dis 2004; 4: 437-44.

  25. Soriano V, Puoti M, Sulkowski M, et al. Care of patients with hepatitis C and HIV co-infection. Update recommendations from the HIV-HCV International Panel. AIDS 2004; 18: 1-12.

  26. Alberti A, Clumeck N, Collins S, et al. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 2005; 42: 615-24.

  27. Sherman K, Roustrer S, Chung R, Rajicic N. Hepatitis C: prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antiviral Ther 2000; 5 (Suppl 1): 64-5.

  28. Lauer G, Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.

  29. Rockstroh J, Konopnicki D, Soriano V, et al. Hepatitis B and hepatitis C in the EuroSIDA cohort: prevalence and effect on mortality, AIDS, progression and response to HAART. 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, February 2004 [abstract 799].

  30. Hagan H, Thiede H, Weiss N, Hopkins S, Duchin J, Alexander E. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 2001; 91: 42-6.

  31. Ghosn J, Pierre-Francois S, Thibault V, et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 2004; 5: 303-6.

  32. Masur H, Kaplan J, Holmes K. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med 2002; 137: 435-78.

  33. Beld M, Penning M, van Putten M, et al. Low levels of HCV RNA in serum, plasma, and PBMCs of IDUs during long antibody-undetectable periods before seroconversion. Blood 1999; 94: 1183-91.

  34. George S, Gebhardt J, Klinzman D, et al. Hepatitis C viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immun Def Syndr 2002; 31: 154-62.

  35. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon Alpha-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.

  36. Chung R, Andersen J, Volberding P, et al. Peginterferon Alpha-2a plus ribavirin versus interferon alpha-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451-9.

  37. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alpha-2b vs standard interferon alpha-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients. JAMA 2004; 292: 2839-48.

  38. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for treatment of HIV/HCV co-infected patients. AIDS 2004; 18: F27-36.

  39. Soriano V, Pérez-Olmeda M, Ríos P, Núñez M, García-Samaniego J, González-Lahoz J. Hepatitis C virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. AIDS Res Hum Retroviruses 2004; 20: 351-4.

  40. Graham C, Wells A, Liu T, et al. Relationships between HCV-specific immune responses and outcomes of treatment with interferon and ribavirin in HIV-HCV co-infection. 11th Conference on Retroviruses and Opportunistic Infections. February 2004. San Francisco, CA [abstract 111].

  41. Vrolijk J, Kwekkeboom J, Janssen H, et al. Pre-treatment intrahepatic CD8+ cell count correlates with virological response to antiviral therapy in chronic hepatitis C virus infection. J Infect Dis 2003; 188: 1528-32.

  42. Strader D, Wright T, Thomas D, Seeff L. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171.

  43. Wong J, Bennett W, Koff R, Pauker S. Pre-treatment evaluation of chronic hepatitis C. Risks, benefits, and costs. JAMA 1998; 280: 2088-93.

  44. Spinzi G, Minoli G. To biopsy or not to biopsy. Hepatology 2001; 34: 438-9.

  45. Andriulli A, Mangia A, Niro G, Caturelli E. To biopsy or not to biopsy. Hepatology 2001; 34: 438.

  46. Dienstag J. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36 (Suppl): 152-60.

  47. Soriano V, Martín-Carbonero L, García-Samaniego J. Treatment of chronic hepatitis C virus infection: we must target the virus or liver fibrosis? AIDS 2003; 17: 751-3.

  48. Kuehne F, Bethe U, Freedberg K, Goldie S. Treatment for hepatitis C virus in HIV-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med 2002; 162: 2545-56.

  49. Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn 2005; 5: 15-21.

  50. Myers R, Benhamou Y, Imbert-Bismut F, et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 2003; 17: 721-5.

  51. Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.

  52. Soriano V, García-Samaniego J, Bravo R, et al. Interferon alpha for the treatment of chronic hepatitis C in patients infected with HIV. Hepatitis-HIV Spanish Study Group. Clin Infect Dis 1996; 23: 585-91.

  53. Gao B, Hong F, Radaeva S. Host factors and failure of interferon treatment in hepatitis C virus. Hepatology 2004; 39: 880-90.

  54. Zeuzem S. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well? Ann Intern Med 2004; 140: 370-81.

  55. Lee S, Bain V, Peltekian K, et al. Peginterferon alfa-2a (40 kD) (PEGASYS®) plus ribavirin (COPEGUS®) in cirrhotic patients with chronic hepatitis C: results of a Canadian multicenter open-label expanded access program. J Hepatol 2005; 42(Suppl 2): 211 [abstract 576].

  56. Lim J, Imperial J. Safety and efficacy of antiviral therapy in patients with decompensated cirrhosis associated with chronic hepatitis C infection. J Hepatol 2005; 42(Suppl 2): 211 [abstract 579].

  57. Sylvestre D. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002; 67: 117-23.

  58. Backmund M, Meyer K, von Zielonka V, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. Hepatology 2001; 34: 188-93.

  59. Edlin B. Prevention and treatment of hepatitis C in injecting drug users. Hepatology 2002; 36(Suppl): 210-9.

  60. Fultz S, Justice A, Butt A, et al. Testing, referral, and treatment patterns for hepatitis C virus coinfection in a cohort of Veterans with HIV infection. Clin Infect Dis 2003; 36: 1039-46.

  61. Rauch A, Egger M, Reichen J, Furrer H, and the Swiss HIV Cohort Study. Chronic hepatitis C in HIV-infected patients: low eligibility and applicability of therapy with pegylated interferon-á plus ribavirin. J Acquir Immune Defic Syndr 2005; 38: 238-240.

  62. Restrepo A, Johnson T, Widjaja D, et al. The rate of treatment of chronic hepatitis C in patients coinfected with HIV in an urban medical centre. J Viral Hepatitis 2005; 12: 86-90.

  63. Butt A, Wagener M, Shakil A, Ahmad J. Reasons for non-treatment of hepatitis C in veterans in care. J Viral Hepatitis 2005; 12: 81-85.

  64. Fried M, Shiffman M, Reddy R, et al. Peginterferon alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  65. Davis G, Albright J, Cook S, Rosenberg D. Early virologic response to treatment with peginterferon alpha-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.

  66. Torriani F, Ribeiro R, Gilbert T, et al. HCV and HIV dynamics during HC treatment in HIV/HCV coinfection. J Infect Dis 2003; 188: 1498-507.

  67. Ballesteros A, Franco S, Fuster D, et al. Early HCV dynamics on peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches. AIDS 2004; 18: 59-66.

  68. Moreno L, Quereda C, Morena A, et al. Pegylated interferon-a 2b + ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 2004; 18: 67-73.

  69. Soriano V, Nuñez M, Camino N, et al. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. Antivir Ther 2004; 9: 505-9.

  70. Neumann A, Lam N, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon alpha therapy. Science 1998; 282: 103-7.

  71. Pawlotsky J. Use and interpretation of virological tests for hepatitis C. Hepatology 2002; 36(Suppl): 65-73.

  72. Talal A, Shata M, Markatou M, et al. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immun Defic Syndr 2004; 35: 103-13.

  73. Fried M. Side effects of therapy of hepatitis C and their management. Hepatology 2002; 36(Suppl): 237-44.

  74. Manns M, McHutchison J, Gordon S, et al. Peginterferon alpha-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.

  75. Hadziyannis S, Sette H, Morgan T, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C. Ann Intern Med 2004; 140: 346-55.

  76. Dieterich D. Treatment of hepatitis C and anemia in HIV-infected patients. J Infect Dis 2002; 185(Suppl 2): 128-37.

  77. Afdhal N, Dieterich D, Pockros P, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients. A prospective, double-blind randomized controlled study. Gastroenterology 2004; 126: 1302-11.

  78. Gish R, Arora S, Nelson D, Fernández H, Lamon K. Safety and efficacy of Viramidine in combination with pegylated interferon alpha-2a for treatment of hepatitis C in therapy-naive patients. J Hep 2004; 40(Suppl 1): 141-2 [Abstract 479].

  79. Pesce A, Taillan B, Rosenthal E. Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients. Lancet 1993; 341: 1597.

  80. Lafeuillade A, Hittinger G, Chapadaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001; 357: 280-1.

  81. Moyle G. Hyperlactatemia and lactic acidosis during antiretroviral therapy: causes, management and possible etiologies. AIDS Rev 2001; 3: 150-6.

  82. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon therapy. AIDS 2004; 18:F21-5.

  83. Rendon A, Nuñez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virological response in HIV/hepatitis C virus-coinfected patients. J Acquir Immun Defic Syndr (in press).

  84. Zingman B, Morales H, Rodriguez F, et al. HCV evaluation and treatment can be improved by a multidisciplinary HIV/HCV co-infection program: results from the first year of a program co-located at an urban HIV primary care clinic. Gastroenterology 2005; 128(Suppl 2): A-726.

  85. Breilh D. Plasma target concentration of ribavirin in HCV/HIV-co-infected patients. 12th Conference on Retroviruses and Opportunistic Infections. February 22-25, 2005. Boston, MA [abstract 928].

  86. Brouwer J, Nevens F, Bekkering F, et al. Reduction of relapse rates by 18-month treatment in chronic hepatitis C: a Benelux randomized trial in 300 patients. J Hepatol 2004; 40: 689-95.

  87. Drusano G, Preston S. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis 2004; 189: 964-70.

  88. Planas R, Fuster D, González J, et al. Multicenter pilot study to assess the efficacy and safety of prolonging treatment with peginterferon alpha 2 a (Pegasys) and ribavirin (Copegus) in HIV and HCV coinfected patients without early virological response. Gastroenterology 2005; 128(Suppl 2): A-682.

  89. Afdhal N, Rodriguez-Torres M, Lawitz E, et al. Enhanced antiviral efficacy for valopicitabine (NM283) plus peg-interferon in hepatitis C patients with HCV genotype-1 infection: results of a phase IIa multicenter trial. J Hepatol 2005; 42(Suppl 2): 211 [abstract 93].

  90. Reesink H, Zeuzem S, Vliet A, et al. Initial results of a phase 1 B, multiple-dose study of VX-950, a hepatitis C virus protease inhibitor. Gastroenterology 2005; 128(Suppl 2): A-697.

  91. Bacon B, McHutchinson J, Gordon S, et al. Safety, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of CPG 10101 (Actilonä), a novel TLR9 agonist: comparison in normal volunteers and HCV infected individuals. Gastroenterology 2005; 128(Suppl 2): A-696.

  92. Blatt L, Cheung E, Radhakrishnan R, Ibarra L, Faris-Young S. A phase 1, single-blind, dose-escalating study of the safety and pharmacokinetics of a single injection of pegylated interferon Alpha 1 in healthy volunteers. Gastroenterology 2005; 128(Suppl 2): A-713.




2020     |     www.medigraphic.com